Cravath, Goodwin Advise On J&J's $3B Cancer Drug Play
Cravath-advised Johnson & Johnson said Monday it has agreed to pay $3.05 billion in cash for Goodwin-led Halda Therapeutics, a biotech developing a clinical-stage therapy for prostate cancer....To view the full article, register now.
Already a subscriber? Click here to view full article